Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects

Amy M Trottier, Sonia Cerquozzi, Carolyn J Owen Division of Hematology and Hematological Malignancies, University of Calgary, Foothills Medical Centre, Calgary, AB, Canada Abstract: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare CD4+ CD56+ myeloid malignancy that is challenging to di...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Trottier AM, Cerquozzi S, Owen CJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	BPDCN Myeloid Neoplasm Cutaneous Dendritic cell Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/1fe637932624409aa9ee5373bb4d3038
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1fe637932624409aa9ee5373bb4d3038
record_format	dspace
spelling	oai:doaj.org-article:1fe637932624409aa9ee5373bb4d30382021-12-02T07:38:56ZBlastic plasmacytoid dendritic cell neoplasm: challenges and future prospects1179-9889https://doaj.org/article/1fe637932624409aa9ee5373bb4d30382017-12-01T00:00:00Zhttps://www.dovepress.com/blastic-plasmacytoid-dendritic-cell-neoplasm-challenges-and-future-pro-peer-reviewed-article-BLCTThttps://doaj.org/toc/1179-9889Amy M Trottier, Sonia Cerquozzi, Carolyn J Owen Division of Hematology and Hematological Malignancies, University of Calgary, Foothills Medical Centre, Calgary, AB, Canada Abstract: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare CD4+ CD56+ myeloid malignancy that is challenging to diagnose and treat. BPDCN typically presents with nonspecific cutaneous lesions with or without extra-cutaneous manifestations before progressing to leukemia. Currently, there is no standard of care for the treatment of BPDCN and various approaches have been used including acute myeloid leukemia, acute lymphoblastic leukemia, and lymphoma-based regimens with or without stem cell transplantation. Despite these treatment approaches, the prognosis of BPDCN remains poor and there is a lack of prospective data upon which to base treatment decisions. Recent work examining the mutational landscape and gene expression profiles of BPDCN has identified a number of potential therapeutic targets. One such target is CD123, the α subunit of the human interleukin-3 receptor, which is the subject of intervention studies using the novel agent SL-401. Other investigational therapies include UCART123, T-cell immunotherapy, and venetoclax. Prospective trials are needed to determine the best treatment for this uncommon and aggressive neoplasm. Keywords: BPDCN, myeloid, neoplasm, cutaneous, dendritic cellTrottier AMCerquozzi SOwen CJDove Medical PressarticleBPDCNMyeloidNeoplasmCutaneousDendritic cellDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol Volume 7, Pp 85-93 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	BPDCN Myeloid Neoplasm Cutaneous Dendritic cell Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	BPDCN Myeloid Neoplasm Cutaneous Dendritic cell Diseases of the blood and blood-forming organs RC633-647.5 Trottier AM Cerquozzi S Owen CJ Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects
description	Amy M Trottier, Sonia Cerquozzi, Carolyn J Owen Division of Hematology and Hematological Malignancies, University of Calgary, Foothills Medical Centre, Calgary, AB, Canada Abstract: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare CD4+ CD56+ myeloid malignancy that is challenging to diagnose and treat. BPDCN typically presents with nonspecific cutaneous lesions with or without extra-cutaneous manifestations before progressing to leukemia. Currently, there is no standard of care for the treatment of BPDCN and various approaches have been used including acute myeloid leukemia, acute lymphoblastic leukemia, and lymphoma-based regimens with or without stem cell transplantation. Despite these treatment approaches, the prognosis of BPDCN remains poor and there is a lack of prospective data upon which to base treatment decisions. Recent work examining the mutational landscape and gene expression profiles of BPDCN has identified a number of potential therapeutic targets. One such target is CD123, the α subunit of the human interleukin-3 receptor, which is the subject of intervention studies using the novel agent SL-401. Other investigational therapies include UCART123, T-cell immunotherapy, and venetoclax. Prospective trials are needed to determine the best treatment for this uncommon and aggressive neoplasm. Keywords: BPDCN, myeloid, neoplasm, cutaneous, dendritic cell
format	article
author	Trottier AM Cerquozzi S Owen CJ
author_facet	Trottier AM Cerquozzi S Owen CJ
author_sort	Trottier AM
title	Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects
title_short	Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects
title_full	Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects
title_fullStr	Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects
title_full_unstemmed	Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects
title_sort	blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/1fe637932624409aa9ee5373bb4d3038
work_keys_str_mv	AT trottieram blasticplasmacytoiddendriticcellneoplasmchallengesandfutureprospects AT cerquozzis blasticplasmacytoiddendriticcellneoplasmchallengesandfutureprospects AT owencj blasticplasmacytoiddendriticcellneoplasmchallengesandfutureprospects
_version_	1718399267349987328

Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects

Ejemplares similares